Aster Insights
Jacqueline Franzese, MPA, is an experienced professional with a diverse background in strategic partnerships, patient services, and public relations. Currently serving as Manager of Strategic Partnerships at Aster Insights since January 2022, Jacqueline previously held various roles at Memorial Sloan Kettering Cancer Center, including Patient Service Supervisor, where significant accomplishments included creating a centralized clinical trials referral system and facilitating genomic testing for pediatric patients. Prior experience as a Senior Account Executive at Gibbs & Soell involved executing large-scale product launches and managing media relations for clients. Jacqueline holds a Master’s Degree in Public Administration from Baruch College and a Bachelor of Science in Mass Communication from Towson University.
This person is not in any offices
Aster Insights
We believe that personalized medicine starts with a complete view of an individual across their lifetime. Our company was founded in 2006 on the unique principle that informed consent from patients entrusting us with a lifetime connection to their health information, paired with deep partnerships across academia and the life sciences industry, would unlock critical advances in curing cancer. Aster Insights leads the Oncology Research Information Exchange Network (ORIEN®), a consortium of the nation’s leading academic cancer centers that conduct Total Cancer Care®, the world’s largest and longest running observational research study in oncology. TCC® serves as the foundation for novel insights that power oncology breakthroughs. As a long-time innovator in oncology, Aster Insights has world-class expertise in accelerating the life cycle of oncology medical product development. Our solutions are based on scientific and clinical intelligence and strengthened by our unique partnership with patients, academia, and industry. We empower our partners to uncover new targets and biomarkers, enhance cancer detection, deepen our understanding of new treatments, discover new indications, and accelerate clinical trials. Together, we are changing the way cancer is studied, treated, and prevented.